<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aline Hébrant</style></author><author><style face="normal" font="default" size="100%">M Lammens</style></author><author><style face="normal" font="default" size="100%">C Van den Broeck</style></author><author><style face="normal" font="default" size="100%">N. D’Haene</style></author><author><style face="normal" font="default" size="100%">J Van den Oord</style></author><author><style face="normal" font="default" size="100%">A. Vanderstichele</style></author><author><style face="normal" font="default" size="100%">A Dendooven</style></author><author><style face="normal" font="default" size="100%">P Neven</style></author><author><style face="normal" font="default" size="100%">K Punie</style></author><author><style face="normal" font="default" size="100%">G Floris</style></author><author><style face="normal" font="default" size="100%">J Van der Meulen</style></author><author><style face="normal" font="default" size="100%">H A Poirel</style></author><author><style face="normal" font="default" size="100%">C Dooms</style></author><author><style face="normal" font="default" size="100%">S Rottey</style></author><author><style face="normal" font="default" size="100%">T Boterberg</style></author><author><style face="normal" font="default" size="100%">L Brochez</style></author><author><style face="normal" font="default" size="100%">MC Burlacu</style></author><author><style face="normal" font="default" size="100%">G Costante</style></author><author><style face="normal" font="default" size="100%">D Creytens</style></author><author><style face="normal" font="default" size="100%">De Paepe, P</style></author><author><style face="normal" font="default" size="100%">R De Pauwn</style></author><author><style face="normal" font="default" size="100%">B Decallonne</style></author><author><style face="normal" font="default" size="100%">F Dedeurwaerdere</style></author><author><style face="normal" font="default" size="100%">H Denys</style></author><author><style face="normal" font="default" size="100%">L Ferdinande</style></author><author><style face="normal" font="default" size="100%">R Forsyth</style></author><author><style face="normal" font="default" size="100%">M Garmyn</style></author><author><style face="normal" font="default" size="100%">T Gevaert</style></author><author><style face="normal" font="default" size="100%">J De Grève</style></author><author><style face="normal" font="default" size="100%">E Govaerts</style></author><author><style face="normal" font="default" size="100%">E Hauben</style></author><author><style face="normal" font="default" size="100%">J Kerger</style></author><author><style face="normal" font="default" size="100%">O Kholmanskikh Van Criekingen</style></author><author><style face="normal" font="default" size="100%">V Kruse</style></author><author><style face="normal" font="default" size="100%">Y Lalami</style></author><author><style face="normal" font="default" size="100%">L Lapeire</style></author><author><style face="normal" font="default" size="100%">P Lefesvre</style></author><author><style face="normal" font="default" size="100%">JP Machiels</style></author><author><style face="normal" font="default" size="100%">B Maes</style></author><author><style face="normal" font="default" size="100%">G Martens</style></author><author><style face="normal" font="default" size="100%">M Remmelink</style></author><author><style face="normal" font="default" size="100%">I Salmon</style></author><author><style face="normal" font="default" size="100%">R Sciot</style></author><author><style face="normal" font="default" size="100%">S Tejpar</style></author><author><style face="normal" font="default" size="100%">K Van de Vijver</style></author><author><style face="normal" font="default" size="100%">L Van de Voorde</style></author><author><style face="normal" font="default" size="100%">I Van den Berghe</style></author><author><style face="normal" font="default" size="100%">A Van den Bruel</style></author><author><style face="normal" font="default" size="100%">K Vandecasteele</style></author><author><style face="normal" font="default" size="100%">L Vanwalleghem</style></author><author><style face="normal" font="default" size="100%">K Vermaelen</style></author><author><style face="normal" font="default" size="100%">R Salgado</style></author><author><style face="normal" font="default" size="100%">E Wauters</style></author><author><style face="normal" font="default" size="100%">B Weynand</style></author><author><style face="normal" font="default" size="100%">Els Van Valckenborgh</style></author><author><style face="normal" font="default" size="100%">Gordana Raicevic</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">P Pauwels</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Algorithms for molecular testing in solid tumours</style></title><secondary-title><style face="normal" font="default" size="100%">Belgian Journal of Medical Oncology (BJMO</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">nov 2019</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">295</style></number><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their relevance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This methodology was applied on different solid tumours for which molecular testing is a clear clinical need.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><section><style face="normal" font="default" size="100%">286</style></section></record></records></xml>